CN Patent

CN116217505B — 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂

Assigned to Nanjing Medical University · Expires 2024-10-01 · 2y expired

What this patent protects

本发明公开了用于诊断或治疗表达前列腺特异性膜抗原(PSMA)癌症的新型标记靶向剂，具体涉及通式Ⅰ所示的化合物，或其旋光异构体、药学上可接受的盐和/或溶剂化物，它们的制备方法以及含有所述化合物的药物组合物。本发明还涉及该类化合物及其药学上可接受的盐、溶剂化物或其前药在治疗中作为治疗表达PSMA癌症中的用途。

USPTO Abstract

本发明公开了用于诊断或治疗表达前列腺特异性膜抗原(PSMA)癌症的新型标记靶向剂，具体涉及通式Ⅰ所示的化合物，或其旋光异构体、药学上可接受的盐和/或溶剂化物，它们的制备方法以及含有所述化合物的药物组合物。本发明还涉及该类化合物及其药学上可接受的盐、溶剂化物或其前药在治疗中作为治疗表达PSMA癌症中的用途。

Drugs covered by this patent

Patent Metadata

Patent number: CN116217505B
Jurisdiction: CN
Classification: —
Expires: 2024-10-01
Drug substance claim: No
Drug product claim: No
Assignee: Nanjing Medical University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.